West explains, “Without the distraction from the Short Kit litigation and with continued strong organic revenue growth from its existing product portfolio, the ~ $100M RePlas opportunity, and the potential for continued organic operating leverage (600-800bps pre-RePlas), we expect VASC shares to continue to work. We raise our target to $49 ($45 prior).”

According to TipRanks, Brooks West is ranked #375 of 4,079 analysts. West maintains a success rate of 71% with an average return of 10.2%.